Novartis Rhapsido(r) (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
October 07, 2026
October 07, 2026
BASEL, Switzerland, Oct. 7 [Category: BizPharmaceuticals] -- Novartis, a pharmaceutical company, posted the following news release:
* * *
Novartis Rhapsido(r) (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
*
* In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with respon . . .
* * *
Novartis Rhapsido(r) (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
*
* In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with respon . . .